Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Non-viral delivery of CRISPR/Cas9 for targeted gene replacement

Award Number: R00EB023979
ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/15/2019
PERIOD OF PERFORMANCE END DATE: 05/31/2023

Group Awards By:

View Award Description

Non-viral delivery of CRISPR/Cas9 for targeted gene replacement - PROJECT SUMMARY Hemophilia A and B are monogenic disorders characterized by the loss of factor VIII (F8) or factor IX (F9) leading to delayed blood clotting and life-long treatment with recombinant clotting factors or blood products. Gene therapy has held promise for treating monogenetic diseases like hemophilia, however, has yet to deliver a curative treatment. Gene delivery barriers and the potential requirement of costly repetitive treatments characterize the drawbacks of technologies currently in the therapeutic pipeline. Gene editing has emerged as a method to make permanent modifications to the host genome. Specifically, RNA-guided nucleases (RGNs) have the potential to correct the genetic basis of a broad range of diseases including hemophilia. However, significant delivery barriers of RGNs or gene-encoded RGNs hinder in vivo gene editing. To date, the most reported in vivo gene editing approaches have used viral delivery vehicles due to robust expression and available tissue tropism. An exciting alternative is the generation of effective non-viral delivery vehicles for RGNs that address the safety concerns of viral delivery vehicles. Therefore, the overall goal of this work is to create a powerful biomacromolecule delivery vector for genome-editing technologies. The central hypothesis of this work is that non-viral delivery of gene-editing nucleases can precisely target replacement genes to safe-harbor loci in the human genome and restore protein expression in hemophilia A or B. The hypothesis will be evaluated with the following specific aims: 1) Characterize viral and non-viral gene replacement safety and efficacy in murine liver. 2) Apply viral and non-viral gene replacement in mouse models of hemophilia, and 3) Develop a screening platform for non-viral gene delivery vehicles. In Aim 1, intravenous delivery of CRISPR/Cas9 will be evaluated for efficient gene replacement. Promising preliminary data for gene delivery to liver has been demonstrated by the PI for viral and non-viral delivery. Both viral and non-viral delivery strategies will be pursued in parallel. Quantitative readouts for single base pair changes, small insertions, and large insertions will be used to assess the efficacy of the delivery routes and determine immune response and off-target activity. In Aim 2, mouse models of hemophilia will be evaluated for genomic modification and recovery of the absent clotting factor. Factor VIII is a model of a large insertion and FIX is a model of a small insertion. In Aim 3, we propose to combine deep sequencing with gene editing to screen libraries of non-viral compounds in small numbers of animals. This method overcomes the limitations of high-throughput in vitro screens that cannot recapitulate complex in vivo delivery barriers. The end result of this work will be an efficient non-viral gene editing toolbox for targeted gene replacement. In addition, this work will generate new strategies for gene editing and gene therapy to improve clinical treatment of hemophilia which may be applied to other genetic diseases.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$2,577 )
2024	2021	UNIVERSITY OF ARKANSAS	1125 W MAPLE ST STE 316	FAYETTEVILLE	AR	72701	WASHINGTON	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	4	2/21/2024	NON-COMPETING CONTINUATION	-$2,577
														Subtotal = -$2,577

Issue Date FY: 2021 ( Subtotal = $241,722 )
2021	2021	UNIVERSITY OF ARKANSAS SYSTEM	1125 WEST MAPLE STE 210	FAYETTEVILLE	AR	72701	WASHINGTON	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	4	6/4/2021	NON-COMPETING CONTINUATION	$241,722
														Subtotal = $241,722

Issue Date FY: 2020 ( Subtotal = $245,990 )
2020	2020	UNIVERSITY OF ARKANSAS SYSTEM	1125 WEST MAPLE STE 210	FAYETTEVILLE	AR	72701	WASHINGTON	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	002	3	7/30/2020	NON-COMPETING CONTINUATION	$136
2020	2020	UNIVERSITY OF ARKANSAS SYSTEM	1125 WEST MAPLE STE 210	FAYETTEVILLE	AR	72701	WASHINGTON	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	3	5/15/2020	NON-COMPETING CONTINUATION	$245,853
2020	2019	UNIVERSITY OF ARKANSAS SYSTEM	1125 WEST MAPLE STE 210	FAYETTEVILLE	AR	72701	WASHINGTON	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	2	11/18/2019	EXTENSION WITH OR WITHOUT FUNDS	$1
														Subtotal = $245,990

Issue Date FY: 2019 ( Subtotal = $247,922 )
2019	2019	UNIVERSITY OF ARKANSAS SYSTEM	1125 WEST MAPLE STE 210	FAYETTEVILLE	AR	72701	WASHINGTON	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	2	8/7/2019	EXTENSION WITH OR WITHOUT FUNDS	$247,922
														Subtotal = $247,922

Grand Total All Awards = $733,057

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Non-viral delivery of CRISPR/Cas9 for targeted gene replacement

Award Number: R00EB023979

ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/15/2019

PERIOD OF PERFORMANCE END DATE: 05/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer